MetaCap

OS Therapies (OSTX) vs Rallybio (RLYB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rallybio (RLYB) has outperformed OS Therapies (OSTX) over the past year, gaining 208.4% versus a loss of 53.0%. Rallybio is the larger company by market cap ($43.3 million vs $42.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OSTX-53.04%RLYB+208.41%
+258%+92%-75%
Nov 21, 20251 yearNov 20, 2026
OSTX-79.92%RLYB+53.47%
+78%-5%-89%
Jul 29, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OSTX versus RLYB key metrics
MetricOSTXRLYB
Share price$0.803$15.47
Market cap$42.00M$43.32M
1-day change-2.12%-0.32%
YTD return-42.64%+181.89%
1-year return-53.04%+208.41%
5-year return—-85.29%
P/E ratio (TTM)—3.36
Forward P/E2.29—
EPS (TTM)$-1.08$4.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$858.00K
Revenue growth (YoY)—+34.91%
Net income (latest FY)$-28.75M$-8.98M
Operating margin—-3853.61%
Net margin—-1046.39%
52-week high$2.25$35.15
52-week low$0.58$7.34
Distance from 52-week high-64.31%-55.99%
Analyst consensusstrong_buy—
Avg. price target upside+958.53%—
Average volume722.66K10.14K
Shares outstanding52.30M2.80M
Employees47
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RLYB has outperformed OSTX by 261.5 percentage points over the past year.

About OS Therapies

OSTX stock →

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Rallybio

RLYB stock →

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

OSTX vs RLYB FAQ

Which is bigger, OS Therapies or Rallybio?

Rallybio (RLYB) is larger, with a market capitalization of $43.32M compared with $42.00M for OS Therapies (OSTX).

Which stock has performed better over the past year, OSTX or RLYB?

RLYB returned +208.41% over the past 12 months, compared with -53.04% for OSTX (price return, excluding dividends). Past performance does not predict future results.

Are OS Therapies and Rallybio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons